Canakinumab MAP in COVID-19 Pneumonia With CRS
NCT04476706 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2021-02-03
Summary
This is a global Managed Access Program (MAP) to provide access to canakinumab to patients with cytokine release syndrome resulting from COVID-19 pneumonia
Conditions
- Cytokine Release Syndrome in COVID-19-induced Pneumonia
Interventions
- DRUG
-
canakinumab
canakinumab
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study
NCT04412291 ·Status: UNKNOWN ·Phase: PHASE2
-
Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia
NCT04459676 ·Status: UNKNOWN ·Phase: PHASE2
-
Urine Pneumococcal Antigen Project
NCT07181200 ·Status: NOT_YET_RECRUITING
-
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)
NCT04317092 ·Status: UNKNOWN ·Phase: PHASE2
-
Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia
NCT04275388 ·Status: UNKNOWN
-
Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia
NCT04469114 ·Status: COMPLETED ·Phase: PHASE3
-
Pneumococcal Carriage in Patients With Lower Respiratory Tract Infection (LRTI)
NCT01861184 ·Status: COMPLETED
-
Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)
NCT05702788 ·Status: WITHDRAWN ·Phase: PHASE2
-
Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia
NCT04750317 ·Status: COMPLETED ·Phase: PHASE2
-
Analysis of the Specificity and Persistence of Nasal Immune Responses to Respiratory Viral Antigens in Immunocompromised and Healthy Cohorts
NCT07295535 ·Status: RECRUITING
-
Baricitinib Therapy in COVID-19
NCT04358614 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19
NCT04912895 ·Status: COMPLETED ·Phase: NA
-
Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS
NCT04359290 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia
NCT04628143 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia
NCT04623021 ·Status: COMPLETED ·Phase: PHASE2
-
Colchicine Counteracting Inflammation in COVID-19 Pneumonia
NCT04322565 ·Status: COMPLETED ·Phase: PHASE2
-
COVID-19 Vaccine Response in Chronic Respiratory Conditions
NCT05313087 ·Status: COMPLETED
-
Efficacy and Safety of SR1375 in Adult Patients With CAP
NCT06577558 ·Status: RECRUITING ·Phase: PHASE2
-
Treatment of Nosocomial COVID-19
NCT04748588 ·Status: TERMINATED ·Phase: PHASE4
-
Tocilizumab in Covid-19 Penumonia in Buenos Aires City
NCT05057962 ·Status: COMPLETED
-
Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab
NCT04359667 ·Status: UNKNOWN
-
Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection
NCT04361903 ·Status: UNKNOWN
-
Reduction of COVID 19 Transmission to Health Care Professionals
NCT04462627 ·Status: COMPLETED ·Phase: NA
-
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
NCT06601998 ·Status: RECRUITING
-
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia
NCT04372186 ·Status: COMPLETED ·Phase: PHASE3